We have located links that may give you full text access.
A comprehensive map of single base polymorphisms in the hypervariable LPA Kringle IV-2 copy number variation region.
Journal of Lipid Research 2018 November 10
Lipoprotein(a) concentrations are among the strongest genetic risk factors for cardiovascular disease and present pronounced inter-ethnic and inter-individual differences. About 90% of lipoprotein(a) variance is controlled by the LPA gene, which contains a 5.6 kb large copy number variation (KIV-2 repeat) that generates >40 protein isoforms. Variants within the KIV-2 region are not called in common sequencing projects, leaving up to 70% of the LPA coding region currently unaddressed. To allow a complete assessment of the variability in LPA, we developed a sequencing strategy for this region and report here the first map of genetic variation in the KIV-2 region, a comprehensively evaluated ultra-deep sequencing protocol and an easy-to-use variant analysis pipeline (https://github.com/genepi/lpa-pipeline). We sequenced 123 Central-European individuals and additionally reanalyzed public data of 2,504 individuals from 26 populations. We found dozens of loss-of-function and splice site mutations, as well as >100, partially even common, missense variants. Some coding variants were frequent in one population, but absent in others. This provides novel candidates to explain the large ethnic and individual differences in Lp(a) concentrations. Importantly, our approach and pipeline are applicable also to other similar copy number variable regions, allowing accessing regions, which are not captured by common genome sequencing.
Full text links
Related Resources
Trending Papers
A Systematic Review of Subclinical Hyperthyroidism Guidelines: a Remarkable Range of Recommendations.European Thyroid Journal 2024 May 2
Nutrition in the intensive care unit: from the acute phase to beyond.Intensive Care Medicine 2024 May 22
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment.Cardiac Failure Review 2024
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.Cochrane Database of Systematic Reviews 2024 May 22
Bronchiectasis management in adults: state of the art and future directions.European Respiratory Journal 2024 May 24
Pathophysiological Link and Treatment Implication of Heart Failure and Preserved Ejection Fraction in Patients with Chronic Kidney Disease.Biomedicines 2024 April 31
2024 update in heart failure.ESC Heart Failure 2024 May 29
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app